Discover. Oncology最新文献_第3页

A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase. 派姆单抗联合化疗治疗头颈癌患者的回顾性研究：联合期疗效对后续维持期的影响

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-07 DOI: 10.1007/s12672-025-02256-1

Ken Saijo, Hiroo Imai, Yuki Kasahara, Ryunosuke Numakura, Reio Ueta, Keiju Sasaki, Yuya Yoshida, Sho Umegaki, Sakura Taniguchi, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka

{"title":"A retrospective study of pembrolizumab plus chemotherapy for head and neck cancer patients: influence of response in combination phase on subsequent maintenance phase.","authors":"Ken Saijo, Hiroo Imai, Yuki Kasahara, Ryunosuke Numakura, Reio Ueta, Keiju Sasaki, Yuya Yoshida, Sho Umegaki, Sakura Taniguchi, Kota Ouchi, Keigo Komine, Hidekazu Shirota, Masanobu Takahashi, Chikashi Ishioka","doi":"10.1007/s12672-025-02256-1","DOIUrl":"10.1007/s12672-025-02256-1","url":null,"abstract":"Background: Pembrolizumab plus chemotherapy is considered one of the standard treatment regimens for patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). The regimen comprises up to 6 cycles of pembrolizumab-chemotherapy combination phase and subsequent pembrolizumab maintenance phase. Pembrolizumab-chemotherapy combination confers high response rate, creating favorable conditions for pembrolizumab maintenance phase. This study examined the influence of response in the combination phase on the efficacy in subsequent maintenance phase.Methods: We retrospectively reviewed the medical records of patients with R/M HNSCC who received pembrolizumab plus chemotherapy as a first-line regimen at Tohoku University Hospital, Sendai, Japan. Progression-free survival (PFS) was analyzed when it was divided into the combination and maintenance phases.Results: A total of 44 patients were enrolled. The best overall response was observed in the combination phase in all patients, and the overall response rate was 46.3%. The median PFS was 5.8 months (95% CI: 4.9-7.1). PFS differed significantly according to the response. When analyzed separately, the PFS only in the maintenance phase differed depending on the response of partial response (PR) or stable disease (SD). There was no difference in the number of chemotherapy cycles between patients with PR and SD. Univariate and multivariate analyses showed that the response in the combination phase was significantly associated with PFS in the maintenance phase.Conclusion: In the pembrolizumab plus chemotherapy regimen for patients with R/M HNSCC, the response in the combination phase may be associated with PFS in the maintenance phase.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"479"},"PeriodicalIF":2.8,"publicationDate":"2025-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794961","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The potential of miR-29 in modulating tumor angiogenesis: a comprehensive review. miR-29在调节肿瘤血管生成中的潜力：一项全面的综述。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-06 DOI: 10.1007/s12672-025-02246-3

Rui-Ting Zhou, Xiao-Jie Luo, Xiao-Xin-Ran Zhang, Jiang-Feng Wu, Yi-Ran Ni

{"title":"The potential of miR-29 in modulating tumor angiogenesis: a comprehensive review.","authors":"Rui-Ting Zhou, Xiao-Jie Luo, Xiao-Xin-Ran Zhang, Jiang-Feng Wu, Yi-Ran Ni","doi":"10.1007/s12672-025-02246-3","DOIUrl":"10.1007/s12672-025-02246-3","url":null,"abstract":"MicroRNAs (miRNAs) are a class of short non-coding RNAs that play a crucial role in the post-transcriptional regulation of gene expression. They are associated with various biological processes related to tumors. Among the numerous miRNAs, miR-29 has garnered attention for its role in regulating tumor angiogenesis. In numerous human tumors, miR-29 has been demonstrated to negatively correlate with the capacity for angiogenesis and the degree of malignancy, as well as with the expression levels of pro-angiogenic factors such as vascular endothelial growth factor vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and matrix metalloproteinase (MMP)-2. Multiple studies, utilizing techniques like dual-luciferase reporter assays, have confirmed that miR-29 directly targets the 3'-untranslated region (UTR) of mRNAs for VEGF, PDGF, and MMP-2. Extensive investigations involving tumor cell lines and animal models have shown that the overexpression of miR-29, achieved through miRNA transfection or the introduction of miRNA mimics, effectively inhibits angiogenesis by upregulating these pro-angiogenic factors. Conversely, downregulation of miR-29 using specific inhibitors promotes angiogenesis. While small molecule inhibitors and antibodies targeting VEGF constitute a primary strategy in anti-angiogenesis therapies, miR-29's ability to target multiple pro-angiogenic molecules positions it as a promising candidate for future therapeutic interventions, especially with ongoing advancements in nucleic acid drug design and delivery systems.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"474"},"PeriodicalIF":2.8,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973036/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794329","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

FADS1, a lipid metabolism-related diagnostic biomarker in KIRC. FADS1: KIRC中与脂质代谢相关的诊断生物标志物。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-06 DOI: 10.1007/s12672-025-02255-2

Tianmin Yang, Kai Sun, Fan Peng, Yuhu Hao, Qingjie Bai, Hanpu Yu, Qinghua Xia

{"title":"FADS1, a lipid metabolism-related diagnostic biomarker in KIRC.","authors":"Tianmin Yang, Kai Sun, Fan Peng, Yuhu Hao, Qingjie Bai, Hanpu Yu, Qinghua Xia","doi":"10.1007/s12672-025-02255-2","DOIUrl":"10.1007/s12672-025-02255-2","url":null,"abstract":"Background: Kidney renal clear cell carcinoma (KIRC), the predominant subtype of renal cell carcinoma, poses significant health risks. The rapid progression and resistance to targeted therapies highlight the need for new tumor markers and therapeutic targets. FADS1, part of the fatty acid desaturase family, regulates fatty acid synthesis and participates in lipid metabolism. However, its role in KIRC is not well-studied.Methods: The study utilized bioinformatics analysis through the TCGA database and other platforms to identify FADS1 expression levels in KIRC. Twenty pairs of KIRC clinical tissue samples were used for qPCR verification. Meanwhile, eight pairs of KIRC clinical tissue samples were used for Western blot verification. Conduct statistical evaluation, including Wilcoxon rank sum test and Kaplan-Meier analysis, to explore the correlation between FADS1 expression and clinical pathological features and immune infiltration. In addition, in vitro experiments were conducted to confirm the biological function of FADS1.Results: The findings indicated that FADS1 is highly expressed in KIRC and contributes to tumor development. FADS1's role in lipid metabolism leads to lipid accumulation within tumor cells, which may influence the occurrence and progression of KIRC. TIMER analysis revealed a correlation between FADS1 expression and the infiltration levels of various immune cells, indicating its potential role in modulating immune characteristics.Conclusion: FADS1 could serve as a prognostic biomarker associated with immunity in KIRC, highlighting its potential as a diagnostic and therapeutic target. The study underscores the importance of further research into FADS1's role in lipid metabolism and immune infiltration to develop effective therapeutic strategies.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"475"},"PeriodicalIF":2.8,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11973044/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794325","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Developing a prognostic nomogram for primary thyroid lymphoma: insights from a large retrospective study. 发展原发性甲状腺淋巴瘤的预后图：来自一项大型回顾性研究的见解。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-06 DOI: 10.1007/s12672-025-02211-0

Ying Gao, Jinmiao Wang, Weijie Tao, Shoujun Wang, Hai Xie, Ran Duan, Jie Hao, Ming Gao

{"title":"Developing a prognostic nomogram for primary thyroid lymphoma: insights from a large retrospective study.","authors":"Ying Gao, Jinmiao Wang, Weijie Tao, Shoujun Wang, Hai Xie, Ran Duan, Jie Hao, Ming Gao","doi":"10.1007/s12672-025-02211-0","DOIUrl":"10.1007/s12672-025-02211-0","url":null,"abstract":"Background: Primary thyroid lymphoma (PTL) is a rare and aggressive malignancy with a need for more precise prognostication tools due to the limitations of existing staging systems. This study aims to develop a nomogram to predict overall survival (OS) rates in PTL patients, addressing the gap in personalized treatment protocols.Methods: We analyzed 1469 PTL cases. Cox regression analyses were used to identify key prognostic factors and construct a survival prognostic nomogram. The nomogram's performance was evaluated using receiver operating characteristic (ROC) curves and decision curve analysis. Additionally, a web-based dynamic nomogram was developed to estimate mortality risk for PTL patients.Results: The nomogram exhibited high clinical utility and precision as determined by decision curve analysis and ROC curves. Furthermore, a novel risk stratification system was introduced. Kaplan-Meier survival curves illustrated significant differences among various risk groups, reinforcing the nomogram's substantial clinical value in predicting OS for PTL patients (P < 0.0001). SHAP value analysis clarified each variable's specific impact on the outcome.Conclusions: The nomogram provides a valuable instrument for clinicians to individualize OS predictions for PTL patients, addressing the unmet need for personalized prognostication in this rare malignancy.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"472"},"PeriodicalIF":2.8,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972995/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794966","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Variation in perioperative practice in elective colorectal cancer surgery: opportunities for quality improvement. 择期结直肠癌手术围手术期实践的差异：提高手术质量的机会。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-06 DOI: 10.1007/s12672-025-02254-3

John C Taylor, Hannah Rossington, Rina George, Sarah L Alderson, Philip Quirke, Caroline Thomas, Simon Howell

{"title":"Variation in perioperative practice in elective colorectal cancer surgery: opportunities for quality improvement.","authors":"John C Taylor, Hannah Rossington, Rina George, Sarah L Alderson, Philip Quirke, Caroline Thomas, Simon Howell","doi":"10.1007/s12672-025-02254-3","DOIUrl":"10.1007/s12672-025-02254-3","url":null,"abstract":"Background: Understanding the variation in perioperative care across a population is fundamental to improving the management and outcomes of patients with colorectal cancer. Currently, there is limited individual patient level data available to assess this variation. Therefore, as part of an improvement programme, we conducted an audit to understand perioperative care.Methods: Audit items were developed to cover the pre, intra and postoperative phases of the colorectal cancer surgical pathway and collected for patients undergoing an elective procedure. The audit was conducted at 14 Hospital Trusts, participating in the Yorkshire Cancer Research Bowel Cancer Improvement Programme, located in the Yorkshire and Humber region, North of England.Results: Information on 216 patients were collected. Functional assessment by Cardiopulmonary Exercise Testing varied across the region (performed in 100% patients at three Trusts, but not at all in six Trusts, P < 0.001). The provision of postoperative high dependency and critical care also varied across the region (in seven Trusts ≥ 80% of patients went to a monitored bed or higher level of care; in three Trusts ≥ 90% of patients received ward care, P < 0.001). The median duration of preoperative starvation varied by Trust (2 to 13 h, P < 0.001). The intraoperative dose of opiate administered to patients varied significantly between Trusts (P < 0.001).Conclusions: There is wide variation in both the provision and practice of perioperative care across a large region in the North of England. The findings are informing a programme of improvement science-based work to improve the management and outcomes of patients with colorectal cancer.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"473"},"PeriodicalIF":2.8,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972997/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143794394","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative analysis and prognostication in gastric cancer: unveiling the role of mitochondrial genomics with the MLRScore model. 胃癌的综合分析和预后：MLRScore模型揭示线粒体基因组学的作用。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-05 DOI: 10.1007/s12672-025-02203-0

Yiru Wen, Peng Chen, Yong Wang, Chunyan Lu, Cao Li, Liu Peng, Xiaohong Cheng, Yulan Guo, Jun Quan, Yue Wen, Lie Yang

{"title":"Integrative analysis and prognostication in gastric cancer: unveiling the role of mitochondrial genomics with the MLRScore model.","authors":"Yiru Wen, Peng Chen, Yong Wang, Chunyan Lu, Cao Li, Liu Peng, Xiaohong Cheng, Yulan Guo, Jun Quan, Yue Wen, Lie Yang","doi":"10.1007/s12672-025-02203-0","DOIUrl":"10.1007/s12672-025-02203-0","url":null,"abstract":"Gastric cancer, a leading cause of cancer-related mortality globally, presents significant challenges in prognosis and treatment due to its heterogeneity. This study aimed to elucidate the role of mitochondrial-related genes (MRGs) in gastric cancer and develop a prognostic model. We analyzed RNA sequencing data and clinical information of 412 gastric cancer samples from The Cancer Genome Atlas (TCGA). A comprehensive list of 1136 MRGs was curated from the MitoCarta3.0 database, leading to the identification of 110 differentially expressed MRGs between gastric cancer and normal tissues. Using univariate and multivariate Cox regression analyses, we constructed the Mitochondrial-Related Risk Score (MLRScore), a prognostic model incorporating five key MRGs. The model was validated in training and testing cohorts and exhibited promising prognostic capability. Additionally, we investigated the relationship between MLRScore and immune cell infiltration, somatic mutations, tumor mutation burden (TMB), and response to chemotherapy. The MLRScore was found to correlate with distinct immune landscapes and chemotherapeutic sensitivities, suggesting its potential utility in guiding personalized treatment strategies. Our study not only provides a novel tool for prognostic assessment in gastric cancer but also underscores the importance of mitochondrial dynamics in tumor biology and patient stratification.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"470"},"PeriodicalIF":2.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972275/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Role of emodin to prevent gastrointestinal cancers: recent trends and future prospective. 大黄素预防胃肠癌的作用：近期趋势及未来展望。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-05 DOI: 10.1007/s12672-025-02240-9

Falak Thakral, Bhairav Prasad, Rippin Sehgal, Saurabh Gupta, Ujjawal Sharma, Bikram Jit Singh, Bunty Sharma, Hardeep Singh Tuli, Shafiul Haque, Faraz Ahmad

{"title":"Role of emodin to prevent gastrointestinal cancers: recent trends and future prospective.","authors":"Falak Thakral, Bhairav Prasad, Rippin Sehgal, Saurabh Gupta, Ujjawal Sharma, Bikram Jit Singh, Bunty Sharma, Hardeep Singh Tuli, Shafiul Haque, Faraz Ahmad","doi":"10.1007/s12672-025-02240-9","DOIUrl":"10.1007/s12672-025-02240-9","url":null,"abstract":"Gastrointestinal malignancies are responsible for approximately 35% of all cancer-related deaths, underscoring the critical need to explore pharmacologically active molecules for chemoprevention. Emodin (1,3,8-trihydroxy-6-methylanthraquinone), a natural compound derived from traditional Chinese and Japanese medicine, has recently garnered significant attention for its potential anticancer properties. Emodin exerts its chemoprotective effects through a combination of antioxidative, anti-inflammatory, and anti-proliferative mechanisms. Research indicates that emodin inhibits cancer metastasis, disrupts cell cycle progression, and impairs cancer cell survival. These effects are mediated through the activation of the p38 MAPK/JNK1/2 signaling pathway, the upregulation of pro-apoptotic factors such as Bax/Bcl-2 and caspases, and the enhancement of reactive oxygen species (ROS) levels (Supplementary Fig. 1). To optimize emodin's therapeutic potential, it is crucial to further investigate its underlying mechanisms of action and develop advanced nano-targeted delivery systems to enhance its bioavailability. This review highlights emodin's promise as a chemopreventive agent for gastrointestinal cancers and emphasizes its potential for development into a novel clinical formulation.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"468"},"PeriodicalIF":2.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972247/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788010","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Multi-omics analysis identifies DLX4 as a novel biomarker for diagnosis, prognosis, and immune infiltration: from pan-cancer to renal cancer. 多组学分析发现DLX4是诊断、预后和免疫浸润的一种新的生物标志物：从泛癌到肾癌。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-05 DOI: 10.1007/s12672-025-02258-z

Zengshun Kou, Shuaizhi Zhu, Jiaxi Zhu, Shufei Wang, Yu Zheng, Shengjie Zhou, Zi'ang Si, Hai Zhu

{"title":"Multi-omics analysis identifies DLX4 as a novel biomarker for diagnosis, prognosis, and immune infiltration: from pan-cancer to renal cancer.","authors":"Zengshun Kou, Shuaizhi Zhu, Jiaxi Zhu, Shufei Wang, Yu Zheng, Shengjie Zhou, Zi'ang Si, Hai Zhu","doi":"10.1007/s12672-025-02258-z","DOIUrl":"10.1007/s12672-025-02258-z","url":null,"abstract":"Background: DLX4 is involved in the regulation of embryonic development, but its function in cancer remains unclear. Here, we conducted a pan-cancer analysis to investigate the molecular mechanisms of DLX4, with a particular emphasis on its role in renal cancer.Methods: A comprehensive analysis of DLX4 was performed, focusing on differences in expression, prognostic value, somatic mutations, methylation modifications, and immune landscapes across various cancer types using multiple databases. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes analyses were utilized to explore the potential biological functions. Additionally, we evaluated the expression profile, prognostic significance, and immune infiltration of DLX4 in Kidney Renal Clear Cell Carcinoma (KIRC). The effect of DLX4 on KIRC was further validated by Spatial Transcriptomics, Real-time PCR (RT-PCR), and Immunohistochemistry experiments.Results: DLX4 was found to be upregulated in 26 cancer types and associated with poor prognosis. It was also correlated with tumor mutational burden (TMB), microsatellite instability, mismatch repair, and methylation, and was significantly enriched in pathways related to cell proliferation. In KIRC, DLX4 expression increased along with TMB and immune scores, likely due to the infiltration of regulatory T cells (Tregs) and T-helper 2 (Th2) cells. Spatial transcriptomics revealed a strong correlation between DLX4 localization and tumor cells. Experimental validation confirmed that DLX4 expression is significantly upregulated in renal cancer tissues.Conclusion: Our study explored the mechanisms of DLX4 in pan-cancer, especially in renal clear cell carcinoma, identifying it as a promising biomarker and therapeutic target.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"467"},"PeriodicalIF":2.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972278/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Expression of REV7 has prognostic significance in cervical cancer treated with intensity-modulated radiation therapy. REV7表达在调强放疗宫颈癌患者中具有预后意义。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-05 DOI: 10.1007/s12672-025-02224-9

Ling Chen, Wei Liu, Meihua Wang, Yang Feng, Tiechen Xiao, Yuxing Yang, Xue Huang

{"title":"Expression of REV7 has prognostic significance in cervical cancer treated with intensity-modulated radiation therapy.","authors":"Ling Chen, Wei Liu, Meihua Wang, Yang Feng, Tiechen Xiao, Yuxing Yang, Xue Huang","doi":"10.1007/s12672-025-02224-9","DOIUrl":"10.1007/s12672-025-02224-9","url":null,"abstract":"Background: Human cervical cancer is the fourth most common malignancies among females worldwide. Radiotherapy is crucial in the treatment of cervical cancer. REV7 is associated with the radiosensitivity of cancer cells. We aimed to investigate the relationship between the REV7 expression and the clinical outcome for patients with cervical cancer who received radiation therapy and identify new markers for studying radiosensitivity in cervical cancer.Material and methods: The expression of REV7 in 71 cases of cervical squamous cell carcinoma (CSCC) tissues, 20 paracancerous tissues and 20 normal cervical epithelia tissues were analyzed by qRT-PCR and immunohistochemistry (IHC). Among them, 60 patients who underwent intensity-modulated radiation therapy (IMRT) and met the inclusion and exclusion criteria were divided into groups based on the REV7 IHC score: high-expression and low-expression. The relationship between REV7 expression level and short-term efficacy, recurrence and metastasis was investigated. Meanwhile, univariate, multivariate, and Kaplan-Meier analyses were used to analyze the association of REV7 expression with disease-free survival (DFS) and overall survival (OS).Results: The expression of REV7 is upregulated in CSCC tissues. There was a higher likelihood of progression (pelvic recurrence or distant metastasis) in the group with high REV7 expression (P = 0.024). Moreover, the REV7-high expression patients showed a shorter DFS than the REV7-low expression group (P = 0.011).Conclusions: The higher expression level of REV7 indicates an unfavorable prognosis in cervical cancer patients undergoing IMRT treatment. REV7 could potentially serve as a novel biomarker and therapeutic target for investigating the radiosensitivity of cervical cancer.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"466"},"PeriodicalIF":2.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11972243/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrative analysis of mitochondrial-related gene profiling identifies prognostic clusters and drug resistance mechanisms in low-grade glioma. 线粒体相关基因谱的综合分析确定了低级别胶质瘤的预后簇和耐药机制。

IF 2.8 4区医学

Discover. Oncology Pub Date : 2025-04-05 DOI: 10.1007/s12672-025-02201-2

Xiaozan Chang, Yingxuan Huang, Ying Qu, Yu Guo, Wenwen Fan, Haining Zhen

{"title":"Integrative analysis of mitochondrial-related gene profiling identifies prognostic clusters and drug resistance mechanisms in low-grade glioma.","authors":"Xiaozan Chang, Yingxuan Huang, Ying Qu, Yu Guo, Wenwen Fan, Haining Zhen","doi":"10.1007/s12672-025-02201-2","DOIUrl":"10.1007/s12672-025-02201-2","url":null,"abstract":"Mitochondrial dysfunction has emerged as a critical factor in the progression and prognosis of low-grade glioma (LGG). In this study, we explored the role of mitochondrial-related genes through consensus clustering analysis using multi-omics data from the TCGA, CGGA, and other independent datasets. Patients were categorized into three clusters (Cluster A, B, and C), with Cluster B consistently associated with poorer prognosis. Mutation landscape analysis revealed distinct genetic alterations and copy number variations among clusters, particularly in Cluster B, which exhibited unique genetic signatures. Immune infiltration analysis showed that Cluster B had higher expression levels of immune checkpoint genes, stronger immune evasion activity, and greater immune cell infiltration, suggesting an immunosuppressive tumor microenvironment. Furthermore, we identified mitochondrial-related prognostic markers and developed a MITscore based on gene expression patterns, which stratified patients into high- and low-risk groups. High MITscore groups displayed stronger stemness characteristics, poorer survival outcomes, and differential responses to chemotherapy and immunotherapy. Cross-validation with drug sensitivity and immunotherapy cohorts indicated that high MITscore patients were more sensitive to certain chemotherapeutic agents and responded better to immunotherapy. Finally, using the SRGA method, we identified novel biomarkers (KDR, LRRK2, SQSTM1) closely associated with mitochondrial function, which may serve as potential targets for therapeutic intervention. These findings highlight the critical role of mitochondrial dysfunction in LGG prognosis, tumor microenvironment regulation, and treatment response, providing new avenues for precision oncology.","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"465"},"PeriodicalIF":2.8,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11971116/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143788003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0